The first patient was dosed in the SKYBRIDGE study assessing peluntamig with Tecentriq for advanced small cell lung cancer ...

The bispecific T-cell engager tarlatamab demonstrated favorable antitumor activity in a small cohort with small cell lung ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Mecbotamab vedotin (Mec-V; CAB-AXL-ADC) continues to demonstrate exceptional overall survival (OS) with a 2-year landmark ...

Explore the latest NSCLC new treatments in development, including candidates aimed at tackling hard-to-treat, late-stage lung ...

Julie Brahmer, MD, discusses the unique features of the phase 3 CheckMate 9LA trial in patients with metastatic non–small cell lung cancer.

The potential of computational chemistry to revolutionise cancer treatment in Nigeria represents a paradigm shift in medical ...

Blocking proteins that cause cancer cells to mutate and resist treatment could significantly improve outcomes for some ...

Recursion said it earned its latest milestone payout by identifying differentiated, oral small molecule leads against a ...

Janux Therapeutics, Inc.’s JANX share price has dipped by 10.52%, which has investors questioning if this is right time to buy.